Small Pharmaceutical Stocks
Discover investment opportunities in Small Pharmaceutical Stocks using our Smart AI Filter.
AI is processing your request...
AI is analyzing your request
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Pharmaceutical Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Pharmaceutical Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Pharmaceutical Stocks using our Smart AI Filter.
6 stocks found for "Small Pharmaceutical Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
---|---|---|---|---|---|---|
1.70 Risk measure | ±100.0% Price volatility | -0.6 Valuation | 0.00% Annual yield | |||
1.13 Risk measure | ±91.9% Price volatility | -5.0 Valuation | 0.00% Annual yield | |||
1.22 Risk measure | ±80.6% Price volatility | -1.6 Valuation | 0.00% Annual yield | |||
1.10 Risk measure | ±61.5% Price volatility | 46.4 Valuation | 0.00% Annual yield | |||
0.77 Risk measure | ±68.2% Price volatility | -1.5 Valuation | 0.00% Annual yield | |||
1.39 Risk measure | ±93.2% Price volatility | -1.1 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.
Read moreGalena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read moreEvolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago.
Read moreThe U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics Inc.'s VYNE Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis.
Read moreVistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.
Read moreAcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read more